You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Epidermal growth factor receptor is expressed and active in a subset of acute myeloid leukemia
|
|---|---|
| Published in |
Journal of Hematology & Oncology, August 2016
|
| DOI | 10.1186/s13045-016-0294-x |
| Pubmed ID | |
| Authors |
Hasan Mahmud, Steven M. Kornblau, Arja ter Elst, Frank J. G. Scherpen, Yi Hua Qiu, Kevin R. Coombes, Eveline S. J. M. de Bont |
| Abstract |
The epidermal growth factor receptor (EGFR) inhibitor erlotinib has been shown to induce complete remission of acute myeloid leukemia (AML) in two patients with concurrent lung cancer and raised attention for a role of EGFR in AML whereas a recent phase II clinical study with gefitinib in AML demonstrated a negative result on the outcome. However, from several studies, EGFR expression in AML is poorly defined and the role of EGFR in AML remains unclear. Herein, we report the results of EGFR expression in AML of large cohorts of adult and pediatric AML patients with the data of total protein and phosphorylation levels of EGFR. Our data conclude that there is the expression of EGFR at the protein level in a subset of AML, which was identified to be functionally active in ~15 % of AML patients. This suggests that future studies need to be conducted with a subset of AML patients characterized by high EGFR expression. |
Mendeley readers
The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 23 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 5 | 22% |
| Student > Master | 4 | 17% |
| Other | 3 | 13% |
| Researcher | 2 | 9% |
| Student > Bachelor | 1 | 4% |
| Other | 3 | 13% |
| Unknown | 5 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 30% |
| Biochemistry, Genetics and Molecular Biology | 2 | 9% |
| Engineering | 2 | 9% |
| Computer Science | 1 | 4% |
| Unspecified | 1 | 4% |
| Other | 2 | 9% |
| Unknown | 8 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 March 2019.
All research outputs
#7,494,138
of 22,908,162 outputs
Outputs from Journal of Hematology & Oncology
#503
of 1,193 outputs
Outputs of similar age
#129,105
of 367,316 outputs
Outputs of similar age from Journal of Hematology & Oncology
#11
of 25 outputs
Altmetric has tracked 22,908,162 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,193 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.8. This one has gotten more attention than average, scoring higher than 51% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 367,316 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 49th percentile – i.e., 49% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 25 others from the same source and published within six weeks on either side of this one. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.